At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 77 enrolled
Drug / intervention
ACP-196 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Proof-of-Concept Study of ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer
In Brief
A Phase 2 clinical trial evaluating ACP-196 and ACP-196 in combination with pembrolizumab for Metastatic Pancreatic Cancer. Completed, enrolled 77 participants across 1 site.
Detailed Summary
ACP-196 Alone and in Combination with Pembrolizumab in Subjects with Advanced or Metastatic Pancreatic Cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Pancreatic Cancer
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 2015
Enrollment StartMay 2015
Primary CompletionMar 2017
TodayJul 2026
First PostedFeb 12, 2015
Enrollment StartMay 1, 2015
Primary CompletionMar 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 11.4 years ago
Interventions
ACP-196drug
ACP-196 in combination with pembrolizumabdrug